Your browser doesn't support javascript.
loading
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.
Perricone, Margherita; Palandri, Francesca; Ottaviani, Emanuela; Angelini, Mario; Bagli, Laura; Bellesia, Enrica; Donati, Meris; Gemmati, Donato; Zucchini, Patrizia; Mancini, Stefania; Marchica, Valentina; Trubini, Serena; De Matteis, Giovanna; Di Zacomo, Silvia; Favarato, Mosè; Fioroni, Annamaria; Bolzonella, Caterina; Maccari, Giorgia; Navaglia, Filippo; Gatti, Daniela; Toffolatti, Luisa; Orlandi, Linda; Laloux, Vèronique; Manfrini, Marco; Galieni, Piero; Giannini, Barbara; Tieghi, Alessia; Barulli, Sara; Serino, Maria Luisa; Maccaferri, Monica; Scortechini, Anna Rita; Giuliani, Nicola; Vallisa, Daniele; Bonifacio, Massimiliano; Accorsi, Patrizia; Salbe, Cristina; Fazio, Vinicio; Gusella, Milena; Toffoletti, Eleonora; Salvucci, Marzia; Svaldi, Mirija; Gherlinzoni, Filippo; Cassavia, Francesca; Orsini, Francesco; Martinelli, Giovanni.
Afiliación
  • Perricone M; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Seràgnoli', University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
  • Palandri F; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Seràgnoli', University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
  • Ottaviani E; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Seràgnoli', University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
  • Angelini M; Molecular Hematology Laboratory U.O.C of Hematology Hospital Mazzoni, Ascoli Piceno, Italy.
  • Bagli L; Medical Genetics Unit- Hub Laboratory AUSL Romagna, Pievesestina di Cesena, Italy.
  • Bellesia E; Imaging and Laboratory Diagnostic Department, Clinical Chemistry and Endocrinology Laboratory, Hematology Unit, Oncology and Technology Department, Hospital S. Maria Nuova, IRCCS, Reggio Emilia, Italy.
  • Donati M; Clinical Pathology Laboratory, A.O. Ospedali Riuniti Marche Nord, Pesaro, Italy.
  • Gemmati D; Center Hemostasis and Thrombosis, Section of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Ferrara, Italy.
  • Zucchini P; Department of Medical and Surgical Sciences, Division of Hematology, University of Modena and Reggio Emilia, Modena, Italy.
  • Mancini S; Clinical Hematology Laboratory, Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
  • Marchica V; Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.
  • Trubini S; Clinical Pathology, Molecular Biology Laboratory, and Hematology/Bone Marrow Transplantation Unit, AUSL Piacenza, Piacenza, Italy.
  • De Matteis G; Section of Clinical Biochemistry and Section of Hematology, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Di Zacomo S; Department of Hematology, Blood Bank and Biotechnology, Ospedale Civile Pescara, Pescara, Italy.
  • Favarato M; UOS Molecular Diagnostics, Department of Clinical Pathology, ULSS12 Venetian, Venice, Italy.
  • Fioroni A; UOC laboratory medicine, P.O. San Salvatore, Sulmona, L'Aquila, Italy.
  • Bolzonella C; Department of Oncology, Laboratory of Pharmacology and Molecular Biology, ULSS 18, Rovigo, Italy.
  • Maccari G; Clinical Hematology, Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy.
  • Navaglia F; Department of Laboratory Medicine, University-Hospital of Padova, Padova, Italy.
  • Gatti D; Department of Haematology and BMT, Healthcare Company of South Tyrol, District of Bolzano, Bolzano, Italy.
  • Toffolatti L; Department of Pathology and Haematology, Treviso General Hospital, Treviso, Italy.
  • Orlandi L; Werfen, Milano, Italy.
  • Laloux V; QIAGEN GmbH, Hilden, Germany (Member of The European LeukemiaNet (ELN) Foundation Circle).
  • Manfrini M; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Seràgnoli', University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
  • Galieni P; Molecular Hematology Laboratory U.O.C of Hematology Hospital Mazzoni, Ascoli Piceno, Italy.
  • Giannini B; Medical Genetics Unit- Hub Laboratory AUSL Romagna, Pievesestina di Cesena, Italy.
  • Tieghi A; Imaging and Laboratory Diagnostic Department, Clinical Chemistry and Endocrinology Laboratory, Hematology Unit, Oncology and Technology Department, Hospital S. Maria Nuova, IRCCS, Reggio Emilia, Italy.
  • Barulli S; Clinical Pathology Laboratory, A.O. Ospedali Riuniti Marche Nord, Pesaro, Italy.
  • Serino ML; Center Hemostasis and Thrombosis, Section of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Ferrara, Italy.
  • Maccaferri M; Department of Medical and Surgical Sciences, Division of Hematology, University of Modena and Reggio Emilia, Modena, Italy.
  • Scortechini AR; Clinical Hematology Laboratory, Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
  • Giuliani N; Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.
  • Vallisa D; Clinical Pathology, Molecular Biology Laboratory, and Hematology/Bone Marrow Transplantation Unit, AUSL Piacenza, Piacenza, Italy.
  • Bonifacio M; Section of Clinical Biochemistry and Section of Hematology, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Accorsi P; Department of Hematology, Blood Bank and Biotechnology, Ospedale Civile Pescara, Pescara, Italy.
  • Salbe C; UOS Molecular Diagnostics, Department of Clinical Pathology, ULSS12 Venetian, Venice, Italy.
  • Fazio V; UOC laboratory medicine, P.O. San Salvatore, Sulmona, L'Aquila, Italy.
  • Gusella M; Department of Oncology, Laboratory of Pharmacology and Molecular Biology, ULSS 18, Rovigo, Italy.
  • Toffoletti E; Clinical Hematology, Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy.
  • Salvucci M; Medical Genetics Unit- Hub Laboratory AUSL Romagna, Pievesestina di Cesena, Italy.
  • Svaldi M; Department of Haematology and BMT, Healthcare Company of South Tyrol, District of Bolzano, Bolzano, Italy.
  • Gherlinzoni F; Department of Pathology and Haematology, Treviso General Hospital, Treviso, Italy.
  • Cassavia F; Werfen, Milano, Italy.
  • Orsini F; Werfen, Milano, Italy.
  • Martinelli G; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Seràgnoli', University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
Oncotarget ; 8(20): 32608-32617, 2017 May 16.
Article en En | MEDLINE | ID: mdl-28427233
ABSTRACT
To date, a plenty of techniques for the detection of JAK2V617F is used over different laboratories, with substantial differences in specificity and sensitivity. Therefore, to provide reliable and comparable results, the standardization of molecular techniques is mandatory.A network of 19 centers was established to 1) evaluate the inter- and intra-laboratory variability in JAK2V617F quantification, 2) identify the most robust assay for the standardization of the molecular test and 3) allow consistent interpretation of individual patient analysis results. The study was conceived in 3 different rounds, in which all centers had to blindly test DNA samples with different JAK2V617F allele burden (AB) using both quantitative and qualitative assays.The positivity of samples with an AB < 1% was not detected by qualitative assays. Conversely, laboratories performing the quantitative approach were able to determine the expected JAK2V617F AB. Quantitative results were reliable across all mutation loads with moderate variability at low AB (0.1 and 1%; CV = 0.46 and 0.77, respectively). Remarkably, all laboratories clearly distinguished between the 0.1 and 1% mutated samples.In conclusion, a qualitative approach is not sensitive enough to detect the JAK2V617F mutation, especially at low AB. On the contrary, the ipsogen JAK2 MutaQuant CE-IVD kit resulted in a high, efficient and sensitive quantification detection of all mutation loads. This study sets the basis for the standardization of molecular techniques for JAK2V617F determination, which will require the employment of approved operating procedures and the use of certificated standards, such as the recent WHO 1st International Reference Panel for Genomic JAK2V617F.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Análisis Mutacional de ADN / Janus Quinasa 2 / Laboratorios / Trastornos Mieloproliferativos Tipo de estudio: Prognostic_studies / Qualitative_research País/Región como asunto: Europa Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Análisis Mutacional de ADN / Janus Quinasa 2 / Laboratorios / Trastornos Mieloproliferativos Tipo de estudio: Prognostic_studies / Qualitative_research País/Región como asunto: Europa Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article